Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash from Operations (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Cash from Operations for 2 consecutive years, with 6435815.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 91.65% to 6435815.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2362084.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 77229.0 for FY2025, 100.53% up from the prior year.
  • Cash from Operations for Q4 2025 was 6435815.0 at Neuphoria Therapeutics, down from 3794648.0 in the prior quarter.
  • The five-year high for Cash from Operations was 11453452.0 in Q1 2025, with the low at 6435815.0 in Q4 2025.